Trial · NCT00474812

Dasatinib in Treating Patients With Metastatic Pancreatic Cancer

NCT00474812, Phase 2, Completed, National Cancer Institute (NCI); results first posted 2013-12-23

3 sourcestrials-2026-11-12-0.5.0

Cite this record

ConductScience Library. Dasatinib in Treating Patients With Metastatic Pancreatic Cancer. Trials, record NCT00474812. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT00474812

On this page

Trial

As registered on ClinicalTrials.gov, in the graph's capture of the registry.

Title: Dasatinib in Treating Patients With Metastatic Pancreatic Cancer
NCT number: NCT00474812
Status: Completed
Phases: Phase 2
Enrollment: 51 participants, actual
Lead sponsor: National Cancer Institute (NCI)
Conditions: Adenocarcinoma of the Pancreas, Recurrent Pancreatic Cancer, Stage IV Pancreatic Cancer
Interventions: dasatinib, laboratory biomarker analysis, physiologic testing
First posted: 2007-05-17
Last updated: 2015-05-05
Results first posted: 2013-12-23

Source ClinicalTrials.gov

Registered outcomes5

Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.

List	Outcome	Time frame	Description
Primary	Median Overall Survival	assessed up to 24 months	From the date of onset of treatment to the date of death and to the date of last follow-up for those still alive, assessed up to 24 months
Secondary	Objective Response Rate (Complete Response, Partial Response, or Stable Disease), Evaluated Using the New International Criteria Proposed by the RECIST Committee	Up to 5 years	Response is defined as CR (Complete Response), PR (Partial Response) or SD (Stable Disease) per Response Evaluation Criteria in Solid Tumor (RECIST criteria). Possible evaluations include: CR: Disappearance of all target lesions. PR: At least a 30% decrease in the size of target lesions. SD: neither sufficient shrinkage to qualify as PR nor sufficient increase to qualify as progressive disease (PD). Progressive disease (PD) is defined as: at least a 20% increase in the sum of the LD of target lesions.
Secondary	Median Progression Free Survival (PFS)	Up to 5 years	Number of months patients were free of disease progression, defined as \< 20% increase in the sum of the LD of target lesions nor the appearance of one or more new lesions.
Secondary	Gait Speed	baseline	Gait speed, determined by a 4 meter walk along a properly measured stretch of hallway while being timed with a stopwatch.
Secondary	Gait Speed	at 8 weeks	Gait speed, determined by a 4 meter walk along a properly measured stretch of hallway while being timed with a stopwatch.

Source ClinicalTrials.gov

Outcomes5

Each outcome the trial posted results for, in ClinicalTrials.gov's words.

Type	Outcome	Time frame	Population	Units	Measured as
PRIMARY	Median Overall Survival	assessed up to 24 months	Intent to treat.	months	MEDIAN
SECONDARY	Objective Response Rate (Complete Response, Partial Response, or Stable Disease), Evaluated Using the New International Criteria Proposed by the RECIST Committee	Up to 5 years	Patients that reached first scans at 2 months	participants	NUMBER
SECONDARY	Median Progression Free Survival (PFS)	Up to 5 years	Intent to treat	months	MEDIAN
SECONDARY	Gait Speed	baseline	Participants who were ambulatory at baseline	meters per second	MEAN
SECONDARY	Gait Speed	at 8 weeks	Participants who were ambulatory at 8 weeks	meters per second	MEAN

Source ClinicalTrials.gov

Results by group6

Each measurement the trial posted, group by group, in the words and numbers it posted.

Outcome	Group	Category	Value	Spread	Units
Median Overall Survival	Dasatinib Treatment		4.7	95% Confidence Interval 2.8 to 6.9	months
Objective Response Rate (Complete Response, Partial Response, or Stable Disease), Evaluated Using the New International Criteria Proposed by the RECIST Committee	Dasatinib Treatment	Progressive disease	24		participants
Objective Response Rate (Complete Response, Partial Response, or Stable Disease), Evaluated Using the New International Criteria Proposed by the RECIST Committee	Dasatinib Treatment	Stable Disease	10		participants
Median Progression Free Survival (PFS)	Dasatinib Treatment		2.1	95% Confidence Interval 1.6 to 3.2	months
Gait Speed	Dasatinib Treatment		4.1	Standard Error 0.32	meters per second
Gait Speed	Dasatinib Treatment		4.6	Standard Error 0.64	meters per second

Source ClinicalTrials.gov

Participant flow3

How many started, completed or left each group, period by period.

Period	Milestone	Group	Participants
Overall Study	STARTED	Dasatinib Treatment	51
Overall Study	COMPLETED	Dasatinib Treatment	44
Overall Study	NOT COMPLETED	Dasatinib Treatment	7

Source ClinicalTrials.gov

Adverse events83

Each adverse event the trial posted, group by group: the participants affected out of those at risk.

Type	Event	Organ system	Group	Affected	At risk
other	Abdominal distension	Gastrointestinal disorders	Dasatinib Treatment	4	51
other	Abdominal pain	Gastrointestinal disorders	Dasatinib Treatment	34	51
other	Agitation	Psychiatric disorders	Dasatinib Treatment	3	51
other	Alanine aminotransferase increased	Investigations	Dasatinib Treatment	27	51
other	Alkaline phosphatase increased	Investigations	Dasatinib Treatment	34	51
other	Alopecia	Skin and subcutaneous tissue disorders	Dasatinib Treatment	4	51
other	Anemia	Blood and lymphatic system disorders	Dasatinib Treatment	36	51
other	Anorexia	Metabolism and nutrition disorders	Dasatinib Treatment	34	51
other	Anxiety	Psychiatric disorders	Dasatinib Treatment	7	51
other	Arthralgia	Musculoskeletal and connective tissue disorders	Dasatinib Treatment	5	51

1 to 10 of 83Source ClinicalTrials.gov

See all 83 adverse events

Adverse event totals3

The totals the trial posted for each group.

Total	Group	Affected	At risk
Total, all-cause mortality	Dasatinib Treatment
Total, other adverse events	Dasatinib Treatment	50	51
Total, serious adverse events	Dasatinib Treatment	21	51

Source ClinicalTrials.gov

Papers0

The papers the trial lists on ClinicalTrials.gov.

None in this release.

Grants1

The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.

Project	Title	Principal investigators	Organization	Funder	Fiscal years
U01CA062502	Early Clinical Trials of New Anti-Cancer Agents with Phase I Emphasis	DOWLATI, AFSHIN	CASE WESTERN RESERVE UNIVERSITY	NATIONAL CANCER INSTITUTE	1994 to 2013

Source NIH RePORTER

Trial comparisons0

Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.

None in this release.

Tests0

The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.

None in this release.

Data dates

The day each source was copied for this release.

ClinicalTrials.gov: 2026-11-12; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
NIH grant links: 2026-11-13; NIH RePORTER

Sources 3

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ClinicalTrials.govNo license stated
NIH RePORTER's clinical studies and project filesPublic domain

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ClinicalTrials.govnone stated
NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this trial from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/trials/v1/NCT00474812

GET https://conductscience.org/api/trials/v1/NCT00474812/events?page=2

API reference For AI assistants